{"id":15749,"date":"2026-06-04T01:05:00","date_gmt":"2026-06-03T23:05:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=2a77452cfa20d716f06b5deec9c604ff"},"modified":"2026-06-04T01:05:00","modified_gmt":"2026-06-03T23:05:00","slug":"alkermes-to-participate-in-the-goldman-sachs-47th-annual-global-healthcare-conference","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=15749","title":{"rendered":"Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference"},"content":{"rendered":"<p>DUBLIN--(BUSINESS WIRE)--<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.alkermes.com&amp;esheet=54546911&amp;newsitemid=20260603267022&amp;lan=en-US&amp;anchor=Alkermes+plc&amp;index=1&amp;md5=f93d33fa848b8a78425961aa2c962411\" rel=\"nofollow\" shape=\"rect\">Alkermes plc<\/a> (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Goldman Sachs 47<sup>th<\/sup> Annual Global Healthcare Conference on Wednesday, June 10, 2026 at 10:00 a.m. ET (3:00 p.m. BST). The live webcast may be accessed under the Investors tab on <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.alkermes.com%2F&amp;esheet=54546911&amp;newsitemid=20260603267022&amp;lan=en-US&amp;anchor=www.alkermes.com&amp;index=2&amp;md5=cad77ab9dcc1ace74dc575e6cf6a31eb\" rel=\"nofollow\" shape=\"rect\">www.alkermes.com<\/a> and will be archived for 14 days.<\/p><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260603267022\/en\/2654160\/4\/Alkermes_plc_Logo.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260603267022\/en\/2654160\/22\/Alkermes_plc_Logo.jpg\" \/><\/a><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260603267022\/en\/2654160\/4\/Alkermes_plc_Logo.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260603267022\/en\/2654160\/21\/Alkermes_plc_Logo.jpg\" \/><\/a><p>\n<b><span class=\"bwuline\">About Alkermes plc\n<br\/><\/span><\/b>Alkermes plc (Nasdaq: ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Alkermes\u2019 pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson\u2019s disease. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes\u2019 website at <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.alkermes.com&amp;esheet=54546911&amp;newsitemid=20260603267022&amp;lan=en-US&amp;anchor=www.alkermes.com&amp;index=3&amp;md5=43a451f2ebc64587bd1a6d116d33e4f7\" rel=\"nofollow\" shape=\"rect\">www.alkermes.com<\/a>.<\/p><br\/> <b>Contacts<\/b> <br\/><p>\nAlkermes Contact:\n<br\/>Sandy Coombs\n<br\/>Investor Relations\n<br\/>+1 781 609 6377<\/p>","protected":false},"excerpt":{"rendered":"<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Wednesday, June 10, 2026 at 10:00 a.m. ET (3:00 p.m. BST). The liv&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-15749","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/15749","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15749"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/15749\/revisions"}],"predecessor-version":[{"id":15750,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/15749\/revisions\/15750"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15749"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=15749"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=15749"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}